(Q33435562)

26 July 2017

title

Current gut-directed therapies for irritable bowel syndrome (English)

1 reference

26 July 2017

main subject

irritable bowel syndrome

1 reference

Howard Y Chang

1

1 reference

26 July 2017

Eoin C Kelly

series ordinal

2

1 reference

26 July 2017

Anthony J Lembo

series ordinal

3

1 reference

26 July 2017

publication date

1 July 2006

1 reference

Current treatment options in gastroenterology

26 July 2017

published in

1 reference

26 July 2017

volume

9

1 reference

26 July 2017

issue

4

1 reference

26 July 2017

page(s)

314-323

1 reference

https://scigraph.springernature.com/pub.10.1007/s11938-006-0013-8

26 July 2017

exact match

0 references

cites work

Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11938-006-0013-8

Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11938-006-0013-8

Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects

21 January 2018

1 reference

12 December 2020

Do interventions which reduce colonic bacterial fermentation improve symptoms of irritable bowel syndrome?

1 reference

12 December 2020

An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome

1 reference

12 December 2020

Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study

1 reference

12 December 2020

Colonic transit, bowel movements, stool form, and abdominal pain in irritable bowel syndrome by treatments with calcium polycarbophil.

1 reference

12 December 2020

Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study

1 reference

12 December 2020

Loperamide treatment of the irritable bowel syndrome

1 reference

12 December 2020

Abnormalities of GI transit in bloated irritable bowel syndrome: effect of bran on transit and symptoms

1 reference

12 December 2020

A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome

1 reference

12 December 2020

Meta-analysis: The treatment of irritable bowel syndrome

1 reference

12 December 2020

A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome

1 reference

12 December 2020

Pharmacologic therapy for the irritable bowel syndrome

1 reference

12 December 2020

Tegaserod and ischemic colitis

1 reference

12 December 2020

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

1 reference

12 December 2020

ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia

1 reference

12 December 2020

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

1 reference

12 December 2020

A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome

1 reference

12 December 2020

Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study

1 reference

12 December 2020

Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth.

1 reference

12 December 2020

Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome

1 reference

12 December 2020

Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles

1 reference

12 December 2020

1 reference

12 December 2020

Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome

1 reference

12 December 2020

The epidemiology of irritable bowel syndrome in North America: a systematic review

1 reference

12 December 2020

Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome.

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation

1 reference

12 December 2020

Effects of an alpha(2)-adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans

1 reference

12 December 2020

Functional bowel disorders and functional abdominal pain

1 reference

12 December 2020

Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis

1 reference

12 December 2020

Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome

1 reference

12 December 2020

Management of the irritable bowel syndrome

1 reference

12 December 2020

Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

1 reference

12 December 2020

Towards a better understanding of abdominal bloating and distension in functional gastrointestinal disorders

1 reference

12 December 2020

What is the benefit of coarse wheat bran in patients with irritable bowel syndrome?

1 reference

12 December 2020

Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time

1 reference

12 December 2020

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

1 reference

12 December 2020

A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating

1 reference

12 December 2020

Systematic review: the epidemiology of ischaemic colitis

1 reference

12 December 2020

Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial

1 reference

12 December 2020

Lubiprostone: RU 0211, SPI 0211

1 reference

12 December 2020

Role of loperamide and placebo in management of irritable bowel syndrome (IBS)

1 reference

12 December 2020

A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome

1 reference

12 December 2020

Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome

1 reference

12 December 2020

Alvimopan, a selective peripherally acting mu-opioid antagonist

1 reference

12 December 2020

Towards identifying optimal doses for alpha-2 adrenergic modulation of colonic and rectal motor and sensory function.

1 reference

12 December 2020

Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride)

1 reference

12 December 2020

Origin of gas retention and symptoms in patients with bloating

1 reference

12 December 2020

Effects of asimadoline, a kappa-opioid agonist, on satiation and postprandial symptoms in health

1 reference

12 December 2020

Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study

1 reference

12 December 2020

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

1 reference

12 December 2020

A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome

1 reference

12 December 2020

Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers

1 reference

12 December 2020

Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis

1 reference

12 December 2020

10.1007/S11938-006-0013-8

Identifiers

DOI

1 reference

26 July 2017

1 reference